MX337527B - Derivado de (aza)indol y su uso para propositos medicos. - Google Patents
Derivado de (aza)indol y su uso para propositos medicos.Info
- Publication number
- MX337527B MX337527B MX2009010966A MX2009010966A MX337527B MX 337527 B MX337527 B MX 337527B MX 2009010966 A MX2009010966 A MX 2009010966A MX 2009010966 A MX2009010966 A MX 2009010966A MX 337527 B MX337527 B MX 337527B
- Authority
- MX
- Mexico
- Prior art keywords
- independently represent
- aza
- indole derivative
- prophylactic
- cyano
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describe un compuesto útil como un agente profiláctico o terapéutico para tratar una enfermedad inducida por nivel de ácido úrico anormal en plasma o similar. Específicamente se describe un derivado de (aza)indol representado por la fórmula general (I), un profármaco o sal de él, o similar, el cual tiene una actividad inhibidora de oxidasa xantina y es útil como un agente profiláctico o terapéutico para una enfermedad inducida por nivel de ácido úrico anormal en plasma. En la fórmula (i), T representa un nitro, un ciano o similar; el anillo J representa un arilo o un heteroarilo; Q representa un carboxi, un 5-tetrazolilo o similar; Y representa H, OH, NH2, un halógeno, un nitro, un alquilo, un alcoxi o similar; X1, X2 y X3 representan independientemente CR2 o N; y R1 y R2 representan independientemente un halógeno, un ciano, un haloalquilo, A-D-E-G-N(-D-E-G)2 o similar (en donde A representa un enlace simple, O, S o similar; D y G representan independientemente un alquileno que puede estar sustituido, un cicloalquileno, un heterocicloalquileno, un arileno, un heteroarileno o similar; y E representa un enlace simple, O, S, COO, SO2 o similar).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007104096 | 2007-04-11 | ||
PCT/JP2008/057089 WO2008126898A1 (ja) | 2007-04-11 | 2008-04-10 | (アザ)インドール誘導体及びその医薬用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2009010966A MX2009010966A (es) | 2009-11-02 |
MX337527B true MX337527B (es) | 2016-03-09 |
Family
ID=39863993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009010966A MX337527B (es) | 2007-04-11 | 2008-04-10 | Derivado de (aza)indol y su uso para propositos medicos. |
Country Status (19)
Country | Link |
---|---|
US (4) | US8003647B2 (es) |
EP (2) | EP2133332B1 (es) |
JP (1) | JP5330989B2 (es) |
KR (1) | KR101502957B1 (es) |
CN (1) | CN101679251B (es) |
AU (1) | AU2008239017B2 (es) |
BR (1) | BRPI0810524B8 (es) |
CA (1) | CA2682391C (es) |
CY (1) | CY1114647T1 (es) |
DK (1) | DK2133332T3 (es) |
ES (1) | ES2431815T3 (es) |
HK (1) | HK1140197A1 (es) |
HR (1) | HRP20130900T1 (es) |
MX (1) | MX337527B (es) |
PL (1) | PL2133332T3 (es) |
PT (1) | PT2133332E (es) |
RU (1) | RU2477274C2 (es) |
SI (1) | SI2133332T1 (es) |
WO (1) | WO2008126898A1 (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080066938A (ko) * | 2005-10-07 | 2008-07-17 | 깃세이 야쿠힌 고교 가부시키가이샤 | 질소 함유 복소환 화합물 및 그것을 함유하는 의약 조성물 |
CN101679251B (zh) * | 2007-04-11 | 2013-10-02 | 橘生药品工业株式会社 | (氮杂)吲哚衍生物及其医药用途 |
KR20100092909A (ko) * | 2009-02-13 | 2010-08-23 | 주식회사 엘지생명과학 | 잔틴 옥시다제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물 |
EP2415771B1 (en) * | 2009-03-31 | 2013-07-31 | Kissei Pharmaceutical Co., Ltd. | Indolizine derivative and use thereof for medical purposes |
KR101256018B1 (ko) | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
TWI423962B (zh) * | 2009-10-07 | 2014-01-21 | Lg Life Sciences Ltd | 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物 |
AR081930A1 (es) * | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
US9643969B2 (en) | 2010-09-29 | 2017-05-09 | Kissei Pharmaceutical Co., Ltd. | (aza)indolizine derivative and pharmaceutical use thereof |
EP2669270B1 (en) | 2011-01-28 | 2018-01-03 | Sato Pharmaceutical Co., Ltd. | Indole-related compounds as urat1 inhibitors |
TWI548630B (zh) * | 2011-04-06 | 2016-09-11 | Lg生命科學有限公司 | 1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-羧酸結晶型及其製造方法 |
US9115144B2 (en) | 2011-08-24 | 2015-08-25 | Kissei Pharmaceutical Co., Ltd. | Fused heterocyclic derivative and pharmaceutical use thereof |
WO2013061962A1 (ja) | 2011-10-24 | 2013-05-02 | 武田薬品工業株式会社 | 二環性化合物 |
KR102226489B1 (ko) * | 2012-07-27 | 2021-03-11 | 사토 파머슈티컬 가부시키가이샤 | 디플루오로메틸렌 화합물 |
CN103980267B (zh) * | 2013-02-08 | 2018-02-06 | 镇江新元素医药科技有限公司 | 一类新型黄嘌呤氧化酶抑制剂的化合物及其药物组合物 |
WO2014132994A1 (ja) * | 2013-02-27 | 2014-09-04 | キッセイ薬品工業株式会社 | 含窒素複素環誘導体の製造方法およびその製造中間体 |
WO2015025914A1 (ja) * | 2013-08-22 | 2015-02-26 | キッセイ薬品工業株式会社 | インドール誘導体の塩及びその結晶 |
JP6823359B2 (ja) * | 2014-06-09 | 2021-02-03 | キッセイ薬品工業株式会社 | インドール誘導体の塩及びその結晶 |
US10266496B2 (en) | 2015-09-02 | 2019-04-23 | Sunshine Lake Pharma Co., Ltd. | Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereof |
CN106008488B (zh) * | 2016-05-20 | 2018-10-30 | 广东东阳光药业有限公司 | 氰基吲哚类衍生物及其制备方法和用途 |
AU2017270858B2 (en) * | 2016-05-23 | 2019-09-19 | Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. | Thiophene, manufacturing method thereof, and pharmaceutical application of same |
CN106045898B (zh) * | 2016-06-28 | 2019-05-24 | 广东东阳光药业有限公司 | 一种吲哚类化合物及其制备方法和用途 |
WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
CN107501162B (zh) * | 2017-07-07 | 2021-06-25 | 浙江工业大学 | 一种n-酰基取代的吲哚衍生物的制备方法 |
CN107987006B (zh) * | 2017-12-20 | 2021-06-01 | 华润赛科药业有限责任公司 | 吲哚类或氮杂吲哚类衍生物、其制备方法和应用 |
CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
EP4053114A4 (en) * | 2019-10-30 | 2023-10-25 | Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. | THIOPHENE DERIVATIVES AS XANTHINE OXIDASE INHIBITORS AND THEIR USE |
CN111072634B (zh) * | 2020-01-03 | 2022-07-22 | 中国医科大学 | 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用 |
MX2023003677A (es) * | 2020-09-30 | 2023-06-22 | Fl2022 001 Inc | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. |
TW202336015A (zh) * | 2020-11-04 | 2023-09-16 | 南韓商Lg化學股份有限公司 | 唑-4-羧酸結晶之製備方法及包含彼之醫藥組成物 |
AR124178A1 (es) * | 2020-12-01 | 2023-02-22 | Lg Chemical Ltd | Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación |
JP2023551524A (ja) * | 2020-12-01 | 2023-12-08 | エルジー・ケム・リミテッド | 1-(3-シアノ-1-イソプロピル-インドール-5-イル)ピラゾール-4-カルボン酸を含む経口用製剤、およびその製造方法 |
EP4324459A4 (en) * | 2021-04-16 | 2024-08-07 | Lg Chemical Ltd | ORAL FORMULATION CONTAINING 1-(3-CYANO-1-ISOPROPYL-INDOL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID |
KR20220147529A (ko) * | 2021-04-27 | 2022-11-03 | 주식회사 엘지화학 | 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법 |
US20240239768A1 (en) * | 2021-04-27 | 2024-07-18 | Lg Chem, Ltd. | Method for preparing xanthine oxidase inhibitor |
MX2023014357A (es) * | 2021-06-15 | 2023-12-15 | Lg Chemical Ltd | Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilo. |
AR126164A1 (es) * | 2021-06-17 | 2023-09-27 | Lg Chemical Ltd | Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico |
TWI822151B (zh) * | 2021-07-02 | 2023-11-11 | 南韓商Lg化學股份有限公司 | 製備黃嘌呤氧化酶抑制劑的方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3370063A (en) | 1964-10-05 | 1968-02-20 | Mcneilab Inc | Substituted dimethoxy indoles and method of making the same |
HUT74464A (en) * | 1993-10-12 | 1996-12-30 | Du Pont Merck Pharma | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof, and pharmaceutical compositions containing them |
US5696143A (en) | 1994-09-20 | 1997-12-09 | Talley; John J. | Benz G! indazolyl derivatives for the treatment of inflammation |
ID21775A (id) * | 1996-10-25 | 1999-07-22 | Yoshitomi Pharmaceutical | Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya |
JP2000001431A (ja) | 1998-06-15 | 2000-01-07 | Kotobuki Seiyaku Kk | 尿酸排泄剤 |
US6573262B2 (en) | 2000-07-10 | 2003-06-03 | Bristol-Myers Sqibb Company | Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives |
ES2250422T3 (es) | 2000-07-10 | 2006-04-16 | Bristol-Myers Squibb Company | Composicion y actividad antiviral de derivados de piperazina indoloxoaceticos sustituidos. |
DE10053275A1 (de) * | 2000-10-27 | 2002-05-02 | Dresden Arzneimittel | Neue 7-Azaindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung |
SE0301372D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
SE0302232D0 (sv) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
US9303300B2 (en) | 2005-09-30 | 2016-04-05 | Mitsubishi Shindoh Co., Ltd. | Melt-solidified substance, copper alloy for melt-solidification and method of manufacturing the same |
KR20080066938A (ko) | 2005-10-07 | 2008-07-17 | 깃세이 야쿠힌 고교 가부시키가이샤 | 질소 함유 복소환 화합물 및 그것을 함유하는 의약 조성물 |
CN101679251B (zh) * | 2007-04-11 | 2013-10-02 | 橘生药品工业株式会社 | (氮杂)吲哚衍生物及其医药用途 |
-
2008
- 2008-04-10 CN CN2008800189139A patent/CN101679251B/zh active Active
- 2008-04-10 DK DK08740190.7T patent/DK2133332T3/da active
- 2008-04-10 KR KR1020097021438A patent/KR101502957B1/ko active IP Right Grant
- 2008-04-10 EP EP08740190.7A patent/EP2133332B1/en active Active
- 2008-04-10 PT PT87401907T patent/PT2133332E/pt unknown
- 2008-04-10 RU RU2009141614/04A patent/RU2477274C2/ru active
- 2008-04-10 JP JP2009509371A patent/JP5330989B2/ja active Active
- 2008-04-10 AU AU2008239017A patent/AU2008239017B2/en active Active
- 2008-04-10 PL PL08740190T patent/PL2133332T3/pl unknown
- 2008-04-10 CA CA2682391A patent/CA2682391C/en active Active
- 2008-04-10 BR BRPI0810524A patent/BRPI0810524B8/pt active IP Right Grant
- 2008-04-10 WO PCT/JP2008/057089 patent/WO2008126898A1/ja active Application Filing
- 2008-04-10 SI SI200831107T patent/SI2133332T1/sl unknown
- 2008-04-10 ES ES08740190T patent/ES2431815T3/es active Active
- 2008-04-10 US US12/595,476 patent/US8003647B2/en active Active
- 2008-04-10 MX MX2009010966A patent/MX337527B/es active IP Right Grant
- 2008-04-10 EP EP11182888.5A patent/EP2402314B1/en active Active
-
2010
- 2010-06-29 HK HK10106337.7A patent/HK1140197A1/xx unknown
-
2011
- 2011-05-26 US US13/116,389 patent/US8466152B2/en active Active
-
2013
- 2013-05-16 US US13/895,634 patent/US8993616B2/en active Active
- 2013-09-23 HR HRP20130900AT patent/HRP20130900T1/hr unknown
- 2013-11-21 CY CY20131101047T patent/CY1114647T1/el unknown
-
2014
- 2014-02-28 US US14/193,911 patent/US8829040B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009010966A (es) | Derivado de (aza)indol y su uso para propositos medicos. | |
MX2009010491A (es) | Derivado heterociclico de 5 miembros y su uso para propositos medicos. | |
PT2415771E (pt) | Derivado de indolizina e sua utilização para fins médicos | |
WO2007026920A3 (en) | Amide derivatives as rock inhibitors | |
WO2008075068A3 (en) | Acylaminopyrazoles as fgfr inhibitors | |
WO2008152014A3 (en) | 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases | |
WO2008126901A1 (ja) | 含窒素複素環化合物およびそれを含有する医薬組成物 | |
MY155517A (en) | Heterocyclic derivatives | |
WO2008093674A1 (ja) | キナーゼ阻害活性を有する新規チアジアゾール誘導体 | |
MX2012000441A (es) | Derivados de 1,2,4-tiazolidin-3-ona y uso en el tratamiento del cancer. | |
WO2008104175A3 (en) | Novel phosphodiesterase inhibitors | |
WO2008099874A1 (ja) | ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法 | |
WO2008147557A3 (en) | Heteroaryl substituted thiazoles and their use as antiviral agents | |
NO20083708L (no) | 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer | |
WO2006127379A3 (en) | Par2-modulating compounds and their use | |
TW200738651A (en) | Cyclohexyl sulfonamide derivatives | |
WO2007115931A8 (de) | Thiazolyl-dihydro-cyclopentapyrazole zur verwendung als pi3-kinase-inhibit0ren | |
PL1685142T3 (pl) | Pochodne kwasu fosfinowego, inhibitory beta-sekterazy do leczenia choroby Alzheimera | |
TW200745063A (en) | Triazolone derivatives | |
WO2009020137A1 (ja) | アミノピラゾールアミド誘導体 | |
WO2006134499A3 (en) | 2-(1h-indolylsulfanyl)-aryl amine derivatives | |
TW200609223A (en) | Process for the preparation of n-piperidino-1,5-diphenylpyrazole-3-carboxamide derivatives | |
WO2007131907A3 (en) | 1h-indol-5-yl-piperazin-1-yl-methanone derivatives | |
WO2008136378A1 (ja) | 新規なスルホンアミド誘導体またはその塩 | |
MX2011004088A (es) | Derivado de anillo fusionado y su aplicacion medica. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |